Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Knighty Tin who wrote (64171)	7/8/1999 1:02:00 AM
From: Merritt	Respond to of 132070

MB: Actually, GZSP had revenues of over $100mm last year and anticipated revenue growth of 15% this year, according to a press release quoting their Pres., Duke Collier. They've stated they plan to initiate 6 clinical trials this year for anti-adhesion applications/products as well as a number of gene therapy products for cardiovascular disease. They also have about $150mm in cash which, along with their revenues, they expect to be enough to see them through their product developments. All the preceding is from the company's PR department...but it's kind of early for them to indulge in hype (not to say that they will later), so it's probably pretty straight skinny. But there's a growing amount of competition in the anti-adhesion markets, so who's to say if they're an undervalued gem with big-time potential, or just another run-of-the-mill biotech that maybe will bring a 60%-100% return over the next 3-5 years...not me.<g>